Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2240055 | 0.94 | LMNA (0.44) | LMNACYP2C19HSD17B10RIPK1DPP4 | |
| SCHEMBL20702359 | 0.85 | RIPK1 (0.37) | LMNACYP2C19HSD17B10RIPK1DPP4 | |
| SCHEMBL23046549 | 0.85 | LMNA (0.41) | LMNAGAAHPGDCYP2C19HSD17B10 | |
| SCHEMBL9917272 | 0.84 | CHRM2 (0.42) | LMNAGAAHPGDCHRM2CHRM4 | |
| SCHEMBL4765068 | 0.82 | DPP4 (0.38) | LMNAGAAHPGDCYP2C19HSD17B10 | |
| SCHEMBL29481524 | 0.82 | LMNA (0.44) | LMNACYP2C19HSD17B10RIPK1DPP4 | |
| SCHEMBL16253007 | 0.81 | GAA (0.48) | LMNAGAAHPGD | |
| SCHEMBL17386569 | 0.80 | LMNA (0.46) | LMNACYP2C19HSD17B10RIPK1DPP4 | |
| SCHEMBL18110887 | 0.80 | LMNA (0.46) | LMNACYP2C19HSD17B10RIPK1DPP4 | |
| SCHEMBL3607188 | 0.80 | LMNA (0.46) | LMNACYP2C19HSD17B10RIPK1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110003202-A | The preparation method and application of imidazo [1,2-a] pyridine derivatives | 华东师范大学 | 2019-07-12 | — | — | CN | claimed |
| CN-112752757-B | Tyrosine amide derivatives as RHO-kinase inhibitors | 奇斯药制品公司 | 2024-01-12 | — | — | CN | disclosed |
| WO-2023227125-A1 | NEW FUSED-HETEROCYCLIC COMPOUND AS CDK INHIBITOR AND USE THEREOF | 杭州德睿智药科技有限公司 | 2023-11-30 | — | — | WO | disclosed |
| CN-116670131-A | PHD inhibitor compounds, compositions, and methods of use | 阿克比治疗有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-116615199-A | Heterocyclic compounds as diacylglycerol kinase inhibitors and uses thereof | 株式会社LG化学 | 2023-08-18 | — | — | CN | disclosed |
| CN-113121524-B | Heterocyclic sulfoxide imine compound, intermediate thereof, preparation method and application | 南京创济生物医药有限公司 | 2023-04-25 | — | — | CN | disclosed |
| CN-112566906-A | Substituted quinazolinone derivatives and their use as positive allosteric modulators of MGLUR4 | 多曼治疗学公司 | 2021-03-26 | — | — | CN | disclosed |
| CN-108699041-B | Imidazole derivative having JNK inhibitory activity and use thereof | 三进制药株式会社 | 2021-03-26 | — | — | CN | disclosed |
| CN-112300172-A | Bruton's tyrosine kinase inhibitors | 比奥根MA公司 | 2021-02-02 | — | — | CN | disclosed |
| CN-107011330-B | Bruton's tyrosine kinase inhibitors | 比奥根MA公司 | 2020-07-03 | — | — | CN | disclosed |
| US-20060276445-A1 | Bicyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| US-20060217361-A1 | Bicyclic 6-alkylidene-penems as beta-lactamase inhibitors | WYETH (US) | 2006-09-28 | — | — | US | disclosed |
| US-7112582-B2 | Bicyclic 6-alkylidene-penems as β-lactamase inhibitors | WYETH (US) | 2006-09-26 | — | — | US | disclosed |
| EP-1499620-A1 | PROCESS FOR PREPARING 6-ALKYLIDENE PENEM DERIVATIVES | Wyeth (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1499621-A1 | BICYCLIC 6-ALKYLIDENE-PENEMS AS BETA-LACTAMASES INHIBITORS | Wyeth (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040132708-A1 | Process for preparing 6-alkylidene penem derivatives | WYETH | 2004-07-08 | — | — | US | disclosed |
| US-20040077622-A1 | Bicyclic 5-alkylidene-penems as beta lactamases inhibitors | WYETH | 2004-04-22 | — | — | US | disclosed |
| CN-1476442-A | Pyridine derivatives with IKB-kinase (IKK-beta) INhibiting activity | — | 2004-02-18 | — | — | CN | disclosed |
| WO-2003093277-A1 | PROCESS FOR PREPARING 6-ALKYLIDENE PENEM DERIVATIVES | WYETH (US) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003093279-A1 | BICYCLIC 6-ALKYLIDENE-PENEMS AS ß-LACTAMASES INHIBITORS | WYETH (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132708-A1 | Process for preparing 6-alkylidene penem derivatives | PGM2, BPGM, MRPL21 | LMNA 769/4885GAA 549/4885HPGD 728/4885 |
| US-20060276445-A1 | Bicyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors | PEPD, MGAM, PGLS | LMNA 288/4885GAA 53/4885HPGD 475/4885 |
| US-20060217361-A1 | Bicyclic 6-alkylidene-penems as beta-lactamase inhibitors | PGLS, BPGM, B2M | LMNA 280/4885GAA 13/4885HPGD 452/4885 |
| US-20040077622-A1 | Bicyclic 5-alkylidene-penems as beta lactamases inhibitors | PGLS, BPGM, B2M | LMNA 296/4885GAA 12/4885HPGD 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.